| Bioactivity | Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3]. |
| Name | Atazanavir sulfate |
| CAS | 229975-97-7 |
| Formula | C38H54N6O11S |
| Molar Mass | 802.93 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Atazanavir sulfate
CAS: 229975-97-7 F: C38H54N6O11S W: 802.93
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved f
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.